[go: up one dir, main page]

PT643775E - Derivados da quinona para aumentar a bioenergia celular - Google Patents

Derivados da quinona para aumentar a bioenergia celular

Info

Publication number
PT643775E
PT643775E PT93909698T PT93909698T PT643775E PT 643775 E PT643775 E PT 643775E PT 93909698 T PT93909698 T PT 93909698T PT 93909698 T PT93909698 T PT 93909698T PT 643775 E PT643775 E PT 643775E
Authority
PT
Portugal
Prior art keywords
pct
animal
present
sec
therapeutic compositions
Prior art date
Application number
PT93909698T
Other languages
English (en)
Inventor
Phillip Nagley
Anthony William Linnane
Ryan Dennis Martinus
Francois Vaillant
Original Assignee
Ct For Molecular Biology And M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct For Molecular Biology And M filed Critical Ct For Molecular Biology And M
Publication of PT643775E publication Critical patent/PT643775E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00Quinones
    • C07C50/02Quinones with monocyclic quinoid structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00Quinones
    • C07C50/02Quinones with monocyclic quinoid structure
    • C07C50/06Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00Quinones
    • C07C50/26Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT93909698T 1992-05-28 1993-05-28 Derivados da quinona para aumentar a bioenergia celular PT643775E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL264292 1992-05-28
AUPL264192 1992-05-28

Publications (1)

Publication Number Publication Date
PT643775E true PT643775E (pt) 2004-10-29

Family

ID=25644259

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93909698T PT643775E (pt) 1992-05-28 1993-05-28 Derivados da quinona para aumentar a bioenergia celular

Country Status (10)

Country Link
US (1) US5981601A (pt)
EP (1) EP0643775B1 (pt)
JP (1) JP3859699B2 (pt)
AT (1) ATE271614T1 (pt)
AU (1) AU666372B2 (pt)
DE (1) DE69333575T2 (pt)
DK (1) DK0643775T3 (pt)
ES (1) ES2224098T3 (pt)
PT (1) PT643775E (pt)
WO (1) WO1993024650A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626177D0 (en) * 1996-12-17 1997-02-05 Univ Aberdeen Channel mediating substrates
DE69841578D1 (de) * 1997-09-16 2010-05-06 Centocor Inc Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US7807654B2 (en) * 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US20050019268A1 (en) * 1999-02-11 2005-01-27 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
US20040224920A1 (en) * 1999-02-23 2004-11-11 The Regents Of The University Of California Methods of treatment of mitochondrial disorders
RU2268732C2 (ru) * 1999-02-23 2006-01-27 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы лечения митохондриальных нарушений
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
WO2002081490A2 (en) * 2001-01-19 2002-10-17 Egea Biosciences, Inc. Computer-directed assembly of a polynucleotide encoding a target polypeptide
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
CA2451163A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Agent for preventing or treating organ functional disorders and order dysfunction
TW200304372A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
AU2003225980A1 (en) * 2002-03-25 2003-10-13 Myriagon Corporation Information management structure
ATE406868T1 (de) * 2003-01-20 2008-09-15 Auriga Internat S A Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
EP2564843B1 (en) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
LT1933821T (lt) * 2005-09-15 2020-11-10 Ptc Therapeutics, Inc. Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
CA2717741C (en) * 2008-03-05 2018-04-03 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
KR100977638B1 (ko) * 2009-06-29 2010-08-24 서울대학교산학협력단 독성분이 있는 배출가스 혼합체에 생존하면서 온실가스를 흡수한 수생식물의 포식자를 이용하는 온실가스 제거 및 바이오 에너지 제조 방법
KR101636946B1 (ko) * 2013-07-29 2016-07-06 한국생명공학연구원 오로트산을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018218287A1 (en) * 2017-05-29 2018-12-06 Woodlinda Pty Ltd Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705239A (en) * 1970-10-16 1972-12-05 Roy B Gregory Pain removing compositions and methods
JPS5697223A (en) * 1979-12-30 1981-08-05 Takeda Chem Ind Ltd Tissue metabolism activator
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
JPS59163316A (ja) * 1983-03-08 1984-09-14 Eisai Co Ltd けいれんの治療・予防剤
JPS60100517A (ja) * 1983-11-08 1985-06-04 Eisai Co Ltd 放射線潰瘍治療剤および方法
IL78611A0 (en) * 1986-04-23 1986-08-31 Yeda Res & Dev Production of polyprenoid and ubiquinone-type compounds
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
WO1992003052A1 (en) * 1990-08-23 1992-03-05 Jariwalla Raxit J Method for suppression of hiv replication by ascorbate for chronic and acute hiv infection
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
US5281628A (en) * 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5460819A (en) * 1991-12-13 1995-10-24 Children's Medical Center Corporation Method for treating PQQ-responsive heavy metal toxicity
JPH1165522A (ja) * 1997-08-25 1999-03-09 Mitsubishi Electric Corp プラズマディスプレイパネルの駆動方法

Also Published As

Publication number Publication date
EP0643775A1 (en) 1995-03-22
DE69333575D1 (de) 2004-08-26
AU666372B2 (en) 1996-02-08
US5981601A (en) 1999-11-09
AU4054593A (en) 1993-12-30
EP0643775B1 (en) 2004-07-21
WO1993024650A1 (en) 1993-12-09
EP0643775A4 (en) 1995-12-27
JP3859699B2 (ja) 2006-12-20
ES2224098T3 (es) 2005-03-01
DE69333575T2 (de) 2005-08-25
DK0643775T3 (da) 2004-09-06
ATE271614T1 (de) 2004-08-15
JPH08500091A (ja) 1996-01-09

Similar Documents

Publication Publication Date Title
PT643775E (pt) Derivados da quinona para aumentar a bioenergia celular
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
HRP960508A2 (en) A method of enhancing cellular production of molecular chaperon,hydroxalamine derivatives useful for enhancing the chaperon production and the preparation thereof
IE862543L (en) Pharmaceutical compositions
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
MX9706380A (es) Guanidinas de acidos alquenil-carboxilicos sustituidos con fenilo, procedimientos para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como un medicamento que las contiene.
MX9307509A (es) Metodo y preparacion farmaceutica para reducir la actividad de las celulas.
CA2284774A1 (en) Theobromine antitussive compositions
ATE84045T1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
ES2125887T3 (es) Procedimiento ortomolecular para tratar la anemia drepanocitica.
DK166323C (da) Griseolsyrederivater og farmaceutiske midler indeholdende disse
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
ES8407321A1 (es) "un procedimiento para preparar un compuesto organico de selenio"
TR200100645T2 (tr) PARP inhibitörleri olarak doymamış hidroksimik asit türevleri.
ATE551058T1 (de) Zusammensetzungen enthaltend tempamine und deren verwendung zum schutz vor oxidativer schädigung
RU94033851A (ru) Вещество, стимулирующее функциональную активность наружных тканей организма
Bembenek THE ANABOLIC EFFECTS OF INSULIN ON MACROMOLECULES OF FRESHLY ISOLATED CHONDROSARCOMA CHONDROCYTES IN VITRO.
TH29868A (th) วิธีการและองค์ประกอบของสารสำหรับทำให้สีของผิวหนังจางลง
Litwack et al. Modification of Lysozyme Thermostability by Cytochrome c Preparations.
JPH07258024A (ja) メラニン生成阻害剤
KR890002101A (ko) N-헤테로사이클릴-4-피페리딘아민 유도체
DE69321473D1 (en) Amylin muteine
AR004353A1 (es) Metodo para medicamentar el sistema de control inflamatorio y reacciones inflamatorias adversas y para fabricar compuestos para el tratamiento de lapatologia de reacciones inflamatorias adversas.
GR1004109B (el) Ενεσιμα διαλυματα παρακεταμολης και καρισοπροδολης ή και παρακεταμολης και κιτρικης ορφεναδρινης